Antiarrhythmic and hypotensive activities of 1-[2-hydroxy-3-(4-phenyl-1- piperazinyl)propyl]-pyrrolidin-2-one (MG-1(R,S)) and its enantiomers

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 455-463

  Sapa, Jacek ^a   Filipek, Barbara ^a   Nowiński, Leszek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiarrhythmic; Enantiomer; Phenylpiperazine pyrrolidine 2 one; adrenoceptor blocking activity

Indexed keywords

1 [2 HYDROXY 3 (4 PHENYL 1 PIPERAZINYL)PROPYL] PYRROLIDIN 2 ONE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BARIUM CHLORIDE; PHENYTOIN; QUINIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; ELECTROCARDIOGRAPHY; ENANTIOMER; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; MOUSE; NONHUMAN; SYSTOLIC BLOOD PRESSURE;

EID: 79955943142     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70512-6     Document Type: Article

References (43)

1. Bernauer M, Ernenputsch I: Antagonistic effects of alpha-adrenoceptor blocking agents on arrhythmias, enzyme release, and myocardial necrosis in isolated rat hearts with coronary occlusion and reperfusion. Naunyn- Schmiedeberg's Arch Pharmacol, 1988, 338, 88-95.
2. Bralet J, Didier JP, Moreau D, Opie LH, Rochette L: Effect of alpha-adrenoceptor antagonists (phentolamine, nicergoline and prazosin) on reperfusion arrhythmias and noradrenaline release in perfused rat heart. Br J Pharmacol, 1985, 84, 9-18. (Pubitemid 15169052)
3. 2-Adrenoceptor antagonist in streptozotocin- and vincristine-induced hyperalgesia. Pharmacol Rep, 2008, 60, 499-507.
4. Clerck F, Rong Lu H, Rossem K, Hermans A, Ammel K: In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol, 2002, 16, 125-140.
5. Colucci WS: Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. Ann Inter Med, 1982, 97, 67-77.
6. Corr PB, Witkowski FX. Arrhythmias associated with reperfusion: basic insights and clinical relevance. J Cardiovasc Pharmacol, 1984, 6, S903-S909. (Pubitemid 15198861)
7. Crumb W, Cavero I: QT interval prolongation by noncardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today , 1999, 7, 270-280.
8. Curtis MJ, Macleod BA,Walker JA: Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol, 1987, 19, 399-419. (Pubitemid 17099003)
9. Darbar D, Roden DM: Future of antiarrhythmic drugs. Curr Opin Cardiol, 2006, 21, 361-367. (Pubitemid 44315070)
10. Elmas E, Ahmad-Nejad P, Weiss C, Neumaier M, Borggrefe M: Plasminogen activator inhibitor-1 (PAI-1), toll-like receptor 4 (TLR4), factor II (FII), FXIII and fibrinogen polymorphisms are not associated with the prevalence of sudden death due to ventricular fibrillation during myocardial infarction. Clin Chem Lab Med, 2008, 46, 1329-1331.
11. Filipek B, Sapa J, Malawska B, Kulig K, Antkiewicz- Michaluk L: Search for new antiarrhythmic and hypotensive compounds. Synthesis, antiarrhythmic, antihypertensive, and alpha-adrenoceptor blocking activity of novel 1-[(2-hydroxy-3-amino)]-propylpyrrolidin-2-one derivatives. Arch Pharm (Weinheim), 1997, 330, 225-231. (Pubitemid 27380463)
12. Haverkamp W, Wichter T, Chen X, Hördt M, Willems S, Rotman B, Hindricks G et al.: The pro-arrhythmic effects of anti-arrhythmia agents (German). Z Kardiol, 1994, 83, 75-85.
13. Heusch G: Alpha-adrenergic mechanisms in myocardial ischemia. Circulation, 1990, 81, 1-13.
14. Kulig K, Sapa J, Macia̧ D, Filipek B, Malawska B: Synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxypropyl]- pyrrolidin- 2-one derivatives with anti-arrhythmic, hypotensive, and alpha-adrenolytic activity. Arch Pharm (Weinheim), 2007, 340, 466-475.
15. Kulig K, Sapa J, Nowaczyk A, Filipek B, Malawska B: Synthesis and pharmacological evaluation of new 1-[3-(4-phenylpiperazin-1-yl)-propyl]- and 1-[3-(4-phenylpiperidine)-propyl]- 3-aryl-3-alkyl-pyrrolidin-2- one derivatives with antiarrhythmic and antihypertensive activity. Acta Pol Pharm Drug Res, 2009, 66, 649-662.
16. Kulig K, Spieces C, Sapa J, Caspers C, Filipek B, Malawska B: Synthesis and pharmacological evaluation of pyrrolidin-2-one derivatives as antiarrhythmic, antihypertensive and alpha-adrenolytic agents. Pharmacol Rep, 2010, 62, 68-85.
17. Kurz T, Yamada KA, DaTorre SD, Corr PB: Alpha1- adrenergic system and arrhythmias in ischaemic heart disease. Eur Heart J, 1991, 12, 88-98.
18. Lamontagne D, Yamaguchi N, Nadeau R, Champlan J, Godin D, Campeau N: Effects of sotalol, (-)-propranolol and prazosin on reperfusion-induced arrhythmias and increased cardiac norepinephrine release. Eur J Pharmacol, 1986, 123, 1-10. (Pubitemid 16050971)
19. Langendorff O: Studies on the mammalian heart (German). Pflügers Arch, 1895, 61, 291-332.
20. Librowski T, Czarnecki R, Jastrzebska M, Sapa J: Effect of monoterpene derivative KP-19 on the pressor activity of catecholamines in rats. Pol J Pharmacol, 2000, 52, 101-105. (Pubitemid 30311779)
21. Malawska B, Kulig K, Filipek B, Sapa J, Macia̧ D, Zygmunt M, Antkiewicz-Michaluk L: Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-[2- hydroxy- or 1-[2-acetoxy-3-arylalkylamino)-propyl]- pyrrolidin-2-one derivatives with adrenolytic activity. Eur J Med Chem, 2002, 37, 183-195
22. 1-adrenoceptor antagonist. Farmaco, 2005, 60, 793-803.
23. Michelotti GA, Price DT, Schwinn DA: Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther, 2000, 88, 281-309. (Pubitemid 32406055)
24. Morganroth J: Early and late proarrhythmia from antiarrhythmic drug therapy. Cardiovasc Drugs Ther, 1992, 6, 11-14.
25. Nattel S, Carlsson L: Innovative approaches to antiarrhythmic drug therapy. Nat Rev Drug Discov, 2006, 5, 1034-1049. (Pubitemid 44835130)
26. Oosterhoff P, Oros A, Vos MA: Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs. Anadolu Kardiyol Derg, 2007, 7, 73-78. (Pubitemid 47028978)
27. Ostadal B: The past, the present and the future of experimental research on myocardial ischemia and protection. Pharmacol Rep, 2009, 61, 3-12.
28. Rich MW: Epidemiology of atrial fibrillation. J Interv Card Electrophysiol, 2009, 25, 3-8.
29. Rich MW, Curtis AB: Atrial fibrillation. Introduction. J Interv Card Electrophysiol, 2009, 25, 1-2.
30. Rohilla A, Singh G, Singh M, Balakumar P: Possible involvement of PKC-delta in the abrogated cardioprotective potential of ischemic preconditioning in hyperhomocysteinemic rat hearts. Biomed Pharmacother, 2010, 64, 195-202.
31. Savelieva I, Camm J: Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace, 2008, 10, 647-665. (Pubitemid 351775283)
32. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J, 2006, 152, 842-850. (Pubitemid 44632936)
33. Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V: Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep, 2009, 61, 154-171.
34. Szekeres L, Papp JG: Antiarrhythmic compounds. Prog Drug Res, 1968, 12, 292-369.
35. Szekeres L, Papp JG: Handbook of Experimental Pharmacology. Eds. Schmier J, Eichler O, Springer Verlag, Berlin, 1975, 131-182.
36. Tolg R, Kurz T, Ungerer M, Schreieck J, Gorge B, Richard G: Influence of alpha- and beta-adrenoceptor antagonists on ventricular fibrillation in ischemic rat hearts. Naunyn- Schmiedeberg's Arch Pharmacol, 1997, 356, 62-68. (Pubitemid 27276153)
37. Van Opstal JM, Leunissen JD, Wellens HJ, Vos MA: Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. Eur J Pharmacol, 2001, 412, 67-76. (Pubitemid 32149771)
38. Vaughan Williams EM: Cardiac electrophysiological effects of selective adrenoceptor stimulation and their possible roles in arrhythmias. J Cardiovasc Pharmacol, 1985, Suppl 5, S61-S64.
39. Vaughan Williams EM: Pharmacology of anti-arrhythmic agents. Pergamon Press, Oxford, 1981, 125-150.
40. Vaughan Williams EM: Classification of antidysrhythmic drugs. Pharmacol Ther B, 1975, 1, 115-138.
41. Vaughan Williams EM: Classifying antiarrhythmic actions: by facts or speculation. J Clin Pharmacol, 1992, 32, 964-977.
42. Vaughan Williams EM: Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. J Clin Pharmacol, 1991, 31, 123-135.
43. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM et al.: The Lambeth Conventions - guide-liner for the study of arrhythmias in ischaemia, infarction and reperfusion. Cardiovasc Res, 1988, 22, 447-455.